Articles

Ocugen-Bharat Biotech’s Covaxin Shows Efficacy Against B.1.617 Variant With the COVID-19 cases exponentially increasing, there is a worrisome climate all over the world. Physicians, doctors, researchers, the whole healthcare and pharmaceutical industry are at their toes fighting the second wave of the coronavirus infection.  It seems a new strain of the virus-containing 2 mutations E484Q and L452R, variant known as B.1.617, is behind the surge in the cases in India, Australia, Germany, Ireland, Belgium, New Zealand, Singapore, Namibia, the U.K., and the U.S. Amidst the news of rising cases and death toll, the duo of Bharat Biotech and Pennsylvania-based Ocu...